TY - JOUR
T1 - Refuting the ticagrelor-aspirin black box warning
T2 - And proposing a ticagrelor early-PCI black box warning
AU - Dinicolantonio, James J.
AU - Serebruany, Victor L.
AU - Tomek, Ales
PY - 2013/10/3
Y1 - 2013/10/3
N2 - Context Ticagrelor, a novel reversible antiplatelet agent, has a black box warning to avoid maintenance doses of aspirin > 100 mg. However, a significant ticagrelor-early percutaneous coronary intervention (PCI) interaction exists. Objective To discuss the inappropriateness of the black box warning for aspirin doses > 100 mg with ticagrelor and the appropriateness (and need) for a black box warning for ticagrelor patients needing early (within 24 hours of randomization) PCI. Results The FDA Complete Response Review for ticagrelor indicates that aspirin doses ≥ 300 mg/daily was not a significant interaction. In the ticagrelor-aspirin ≥ 300 mg cohort, all-cause mortality (through study end) and cardiovascular (CV) mortality (through study end) were not significantly increased (HR = 1.27; 95% CI, 0.84-1.93, p = 0.262 and HR = 1.39; 95% CI:0.87-2.2, p = 0.170), respectively. However, in patients treated with early (within 24 hours) PCI, ticagrelor significantly increased all-cause mortality (30 day: HR = 1.89; 95% CI: 1.26-2.81, p = 0.002, and through study end, HR = 1.41; 95% CI,1.08-1.84, p = 0.012) and increased CV mortality (30 day: HR = 1.31; 95% CI: 0.97-1.77, p = 0.075, and through study end, HR = 1.35; 95% CI, 0.995-1.82, p = 0.054) compared to clopidogrel. Conclusions Early-PCI was more prevalent in the US versus outside-US regions (61% versus 49%). The black box warning for the use of maintenance aspirin doses over 100 mg/daily with ticagrelor is inappropriate and ignores the more important, credible, and highly significant ticagrelor-early PCI adverse interaction in PLATO.
AB - Context Ticagrelor, a novel reversible antiplatelet agent, has a black box warning to avoid maintenance doses of aspirin > 100 mg. However, a significant ticagrelor-early percutaneous coronary intervention (PCI) interaction exists. Objective To discuss the inappropriateness of the black box warning for aspirin doses > 100 mg with ticagrelor and the appropriateness (and need) for a black box warning for ticagrelor patients needing early (within 24 hours of randomization) PCI. Results The FDA Complete Response Review for ticagrelor indicates that aspirin doses ≥ 300 mg/daily was not a significant interaction. In the ticagrelor-aspirin ≥ 300 mg cohort, all-cause mortality (through study end) and cardiovascular (CV) mortality (through study end) were not significantly increased (HR = 1.27; 95% CI, 0.84-1.93, p = 0.262 and HR = 1.39; 95% CI:0.87-2.2, p = 0.170), respectively. However, in patients treated with early (within 24 hours) PCI, ticagrelor significantly increased all-cause mortality (30 day: HR = 1.89; 95% CI: 1.26-2.81, p = 0.002, and through study end, HR = 1.41; 95% CI,1.08-1.84, p = 0.012) and increased CV mortality (30 day: HR = 1.31; 95% CI: 0.97-1.77, p = 0.075, and through study end, HR = 1.35; 95% CI, 0.995-1.82, p = 0.054) compared to clopidogrel. Conclusions Early-PCI was more prevalent in the US versus outside-US regions (61% versus 49%). The black box warning for the use of maintenance aspirin doses over 100 mg/daily with ticagrelor is inappropriate and ignores the more important, credible, and highly significant ticagrelor-early PCI adverse interaction in PLATO.
KW - Clinical Trials
KW - Clopidogrel
KW - Percutaneous Coronary Interventions
KW - Ticagrelor
UR - http://www.scopus.com/inward/record.url?scp=84885623587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885623587&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2013.05.060
DO - 10.1016/j.ijcard.2013.05.060
M3 - Article
C2 - 23727111
AN - SCOPUS:84885623587
SN - 0167-5273
VL - 168
SP - 1721
EP - 1723
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 3
ER -